The study included 1032 patients: 658 denosumab users and 374 oral bisphosphonate users. HealthDay News — For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a ...
Researchers performed a retrospective chart review and survey of 107 patients to compare the efficacy, patient satisfaction, cost and known adverse effects of denosumab versus zoledronic acid, ...
Findings from a phase 3 trial showed denosumab-dssb had comparable efficacy, safety, immunogenicity, PK and PD to Prolia in patients with postmenopausal osteoporosis. Ospomyv is approved to treat ...
The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for osteoporosis and bone loss in various patient populations. Stoboclo and Osenvelt ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results